

Caloxin 2A1 TFA Biochemical

Caloxin 2A1 TFA

CATALOG #
AAA227087


PRODUCT SYNONYMS

Caloxin 2A1 TFA; Caloxin 2A1 TFA biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	DMSO: 100 mg/mL (62.79 mM), Need ultrasonic <1mg/ml refers to the product slightly soluble or insoluble
In vitro	Caloxin 2A1 TFA inhibits Ca^{2+} - Mg^{2+} -ATPase in human erythrocyte leaky ghosts, but it does not affect basal Mg^{2+} -ATPase or Na^{+} - K^{+} -ATPase in the ghosts or Ca^{2+} - Mg^{2+} -ATPase in the skeletal muscle sarcoplasmic reticulum. Caloxin 2A1 TFA also inhibits Ca^{2+} -dependent formation of the 140-kDa acid-stable acylphosphate[1]. Caloxin 2A1 TFA increases airway smooth muscle cells (ASMCs) apoptosis[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
MK-5204, CAS 1207751-75-4



Structure
MK-5204, CAS 1207751-75-4

ADDITIONAL INFORMATION

Related Product Information for Caloxin 2A1 TFA biochemical	Caloxin 2A1 TFA is an extracellular plasma membrane Ca^{2+} -ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg^{2+} -ATPase or Na^{+} - K^{+} -ATPase[1].
References	1. Apgar JM, et al. MK-5204: An orally active beta-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127357.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

